---
title: "Madrigal Pharmaceuticals, Inc. (MDGL.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/MDGL.US.md"
symbol: "MDGL.US"
name: "Madrigal Pharmaceuticals, Inc."
industry: "Biotechnology"
datetime: "2026-04-15T10:42:40.704Z"
locales:
  - [en](https://longbridge.com/en/quote/MDGL.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/MDGL.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/MDGL.US.md)
---

# Madrigal Pharmaceuticals, Inc. (MDGL.US)

## Company Overview

Madrigal Pharmaceuticals, Inc., a biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States. It offers Rezdiffra, a liver-directed thyroid hormone receptor beta agonist for treating MASH. The company was founded in 2016 and is headquartered in West Conshohocken, Pennsylvania.

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Exchange | US Market |
| Website | [www.madrigalpharma.com](https://www.madrigalpharma.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: B
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-04-15T04:30:15.000Z

**Overall: B (0.38)**

**Industry**: Biotechnology

| Metric | Value |
|--------|-------|
| Industry Ranking | 16 / 393 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Growth - Stocks whose main business is in the growth stage.
- **Scale**: Mid - The company has stable operation of a large-cap stock and the high return of a small-cap stock.

**Multi Score**: B

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 432.05% |  |
| Net Profit YoY | 38.12% |  |
| P/B Ratio | 19.98 |  |
| Dividend Ratio | 0.00% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 12043254325.31 |  |
| Revenue | 958403000.00 |  |

#### Multi Score Score: B

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | -42.49% | E |
| Profit Margin | -30.08% | E |
| Gross Margin | 94.14% | A |
| Revenue YoY | 432.05% | A |
| Net Profit YoY | 38.12% | B |
| Total Assets YoY | 20.85% | A |
| Net Assets YoY | -20.11% | E |
| Cash Flow Margin | 65.75% | C |
| OCF YoY | 432.05% | A |
| Turnover | 0.83 | B |
| Gearing Ratio | 52.15% | C |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Madrigal Pharmaceuticals, Inc.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "432.05%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "38.12%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "19.98",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.00%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "12043254325.31",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "958403000.00",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "B",
      "indicators": [
        {
          "name": "ROE",
          "value": "-42.49%",
          "rating": "E"
        },
        {
          "name": "Profit Margin",
          "value": "-30.08%",
          "rating": "E"
        },
        {
          "name": "Gross Margin",
          "value": "94.14%",
          "rating": "A"
        },
        {
          "name": "Revenue YoY",
          "value": "432.05%",
          "rating": "A"
        },
        {
          "name": "Net Profit YoY",
          "value": "38.12%",
          "rating": "B"
        },
        {
          "name": "Total Assets YoY",
          "value": "20.85%",
          "rating": "A"
        },
        {
          "name": "Net Assets YoY",
          "value": "-20.11%",
          "rating": "E"
        },
        {
          "name": "Cash Flow Margin",
          "value": "65.75%",
          "rating": "C"
        },
        {
          "name": "OCF YoY",
          "value": "432.05%",
          "rating": "A"
        },
        {
          "name": "Turnover",
          "value": "0.83",
          "rating": "B"
        },
        {
          "name": "Gearing Ratio",
          "value": "52.15%",
          "rating": "C"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -41.78 | 531/393 | - | - | - |
| PB | 19.98 | 420/393 | 19.44 | 14.07 | 9.36 |
| PS (TTM) | 12.57 | 178/393 | 20.34 | 18.31 | 14.75 |
| Dividend Yield | 0.00% | - | - | - | - |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Kiniksa Pharmaceuticals (KNSA.US) | B | A | A | B | A | A |
| 02 | MiMedx (MDXG.US) | A | B | A | B | B | A |
| 03 | Rigel Pharma (RIGL.US) | A | A | B | B | B | A |
| 04 | CapForce Inc. (CFOR.US) | B | A | A | A | C | A |
| 05 | OpGen (OPGN.US) | B | A | A | A | C | A |

## Institutional View

### Analyst Rating Distribution

> As of 2026-04-14T04:00:00.000Z

Total Analysts: **16**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 11 | 69% |
| Overweight | 3 | 19% |
| Hold | 2 | 13% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 524.99 |
| Highest Target | 964.00 |
| Lowest Target | 529.00 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/MDGL.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/MDGL.US/norm.md)
- [Related News](https://longbridge.com/en/quote/MDGL.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/MDGL.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**